This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.canlet.2009.04.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alzheimer's disease and clinical trials.
J Basic Clin Physiol Pharmacol
January 2024
Department of Pharmacology, 621320 College of Pharmacy JSS Academy of Technical Education, Noida, Uttar Pradesh, India.
Article Synopsis
- Alzheimer's disease (AD) is increasingly affecting a large global population, with many genetic factors associated with its progression.
- Despite numerous clinical trials aimed at developing effective treatments, many have failed due to various limitations and confounding factors related to specific drug candidates like thiethylperazine and crenezumab.
- The review aims to analyze these challenges in drug trial outcomes, suggesting that better preliminary assessments could prevent wasted resources in future clinical studies.
Central Neuropathic Mechanisms in Pain Signaling Pathways: Current Evidence and Recommendations.
Adv Ther
May 2020
Department of Pain Medicine, Pain Specialty Group, Newington, NH, USA.
Purpose: This is a comprehensive review of the current literature on central neuropathic pain mechanisms that is secondary to spinal cord injury. It reviews recent and seminal findings on the pathophysiology, diagnosis, and treatment and compares treatment options and recommendations.
Recent Findings: Neuropathic pain (NP) is a common complication of spinal cord injury (SCI).
Identification of genes responsible for RelA-dependent proliferation arrest in human mammary epithelial cells conditionally expressing RelA.
Genom Data
March 2016
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA.
The molecular mechanisms responsible for opposing oncogenic and tumor-suppressor activities of NF-kB are obscure. Semi-quantitative immunohistochemistry of primary breast tumors using antibodies to RelA, the pleiotropic NF-kB factor, and Ki67 revealed a negative correlation between RelA levels and Ki67-index among ER +/HER2 - tumors [1]. Similarly, expression of AURKA, a marker for proliferation, negatively correlates with expression of NFKBIA, a surrogate for RelA expression and activity, in ER +/HER2 - tumors analyzed by The Cancer Genome Atlas [2], [3], [4].
View Article and Find Full Text PDFDoes mouse embryo primordial germ cell activation start before implantation as suggested by single-cell transcriptomics dynamics?
Mol Hum Reprod
March 2016
Group of Computational Biology and Systems Biomedicine, Biodonostia Health Research Institute, Calle Doctor Beguiristain s/n, 20014 San Sebastián - Donostia, Spain IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
Study Hypothesis: Does primordial germ cell (PGC) activation start before mouse embryo implantation, and does the possible regulation of the DNA (cytosine-5-)-methyltransferase 3-like (Dnmt3l) by transcription factor AP-2, gamma (TCFAP2C) have a role in this activation and in the primitive endoderm (PE)-epiblast (EPI) lineage specification?
Study Finding: A burst of expression of PGC markers, such as Dppa3/Stella, Ifitm2/Fragilis, Fkbp6 and Prdm4, is observed from embryonic day (E) 3.25, and some of them, together with the late germ cell markers Zp3, Mcf2 and Morc1, become restricted to the EPI subpopulation at E4.5, while the dynamics analysis of the PE-EPI transitions in the single-cell data suggests that TCFAP2C transitorily represses Dnmt3l in EPI cells at E3.
Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan.
J Thromb Haemost
July 2014
Department of Emergency and Disaster Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
The current management of disseminated intravascular coagulation (DIC) is based on aggressive treatment of the underlying condition and resuscitation with appropriate blood products. Anticoagulant therapy has appeared and disappeared in the different guidelines and important documents detailing the treatment of DIC. For example, Surviving Sepsis Campaign (SSC) guidelines, the 'global standard' for the management of severe sepsis, had recombinant activated protein C highly recommended in the original version, but this was withdrawn in the latest version due to the lack of evidence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!